Surmodics, Inc. (SRDX) Stock Analysis

Surmodics, Inc. (SRDX) Healthcare & Pipeline Overview

Surmodics, Inc. provides surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostics. Operating in the medical device and IVD sectors, the company focuses on enhancing device performance and diagnostic accuracy through its proprietary coating and reagent technologies, serving a global market with a focus on innovation and quality.

What Is the Investment Thesis for SRDX?

Surmodics, Inc. presents a compelling investment thesis based on its established position in surface modification technologies for medical devices and in vitro diagnostics. With a gross margin of 72.8%, the company demonstrates strong pricing power and efficient operations. Key value drivers include the increasing demand for advanced medical devices and diagnostic solutions, particularly in the coronary, peripheral, and neuro-vascular markets. Growth catalysts include the potential approval and commercialization of its drug-coated balloon for peripheral arterial disease treatment, as well as expansion into new geographic markets. However, investors should be aware of the company's negative profit margin of -16.2%, indicating ongoing challenges in achieving profitability. The company's beta of 1.39 suggests higher volatility compared to the overall market. Surmodics' success hinges on its ability to innovate, secure regulatory approvals, and effectively commercialize its products.

Based on FMP financials and quantitative analysis

SRDX Key Highlights

Market Cap of $615M reflects Surmodics' position as a significant player in the medical device and diagnostics market.

• Gross Margin of 72.8% indicates strong pricing power and efficient cost management in its core business segments.
• Negative Profit Margin of -16.2% highlights the company's ongoing challenges in achieving profitability despite high gross margins.
• The company operates in two segments: Medical Device and In Vitro Diagnostics (IVD), providing diversification within the healthcare sector.
• Surmodics' technologies enhance the access, deliverability, and deployment of medical devices, addressing critical needs in coronary, peripheral, and neuro-vascular applications.

Who Are SRDX's Competitors?

SRDX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SRDX's Key Strengths?

Proprietary surface modification technologies.

• Strong intellectual property portfolio.
• Established relationships with medical device manufacturers.
• Expertise in drug-delivery coatings.

What Are SRDX's Weaknesses?

Negative profit margin.

• Reliance on regulatory approvals for new products.
• Limited geographic diversification.
• Smaller scale compared to larger competitors.

What Could Drive SRDX Stock Higher?

Regulatory approval and commercial launch of Surmodics' drug-coated balloon for peripheral arterial disease treatment.

• Expansion of partnerships with medical device manufacturers to integrate Surmodics' technologies into their products.
• Development and launch of new products in the in vitro diagnostics segment.
• Strategic acquisitions of complementary technologies and companies.

What Are the Key Risks for SRDX?

Negative return on equity (-9.5%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Delays or failures in obtaining regulatory approvals for new products.
• Competition from larger medical device manufacturers with greater resources.
• Technological obsolescence and the emergence of alternative technologies.
• Economic downturns affecting healthcare spending and demand for medical devices.
• Product liability claims and litigation related to medical device performance.

What Are the Growth Opportunities for SRDX?

• Expansion of Drug-Coated Balloon (DCB) Technology: Surmodics has a significant growth opportunity in the development and commercialization of its drug-coated balloon technology for treating peripheral arterial disease (PAD). The global DCB market is projected to reach $2 billion by 2028, driven by the increasing prevalence of PAD and the clinical benefits of DCBs over traditional angioplasty. Surmodics' proprietary coating technology and device design provide a competitive advantage in this market. Successful clinical trials and regulatory approvals will be critical for realizing this growth potential. Timeline: Ongoing clinical trials with potential for market entry within the next 2-3 years.
• Strategic Partnerships and Collaborations: Surmodics can leverage strategic partnerships and collaborations to expand its product offerings and market reach. Collaborating with leading medical device manufacturers and diagnostic companies can accelerate the adoption of its technologies and drive revenue growth. These partnerships can also provide access to new markets and distribution channels. The market for medical device collaborations is estimated to be worth billions of dollars annually. Timeline: Ongoing, with potential for new partnerships to be announced in the next 12-18 months.
• Geographic Expansion: Surmodics has the opportunity to expand its geographic presence, particularly in emerging markets such as Asia-Pacific and Latin America. These regions are experiencing rapid growth in healthcare spending and demand for advanced medical technologies. Establishing a presence in these markets through direct sales, distribution agreements, or strategic acquisitions can significantly increase Surmodics' revenue base. The emerging markets medical device market is projected to grow at a CAGR of 8-10% over the next five years. Timeline: Medium-term, with potential for expansion initiatives to be implemented over the next 3-5 years.
• New Product Development in IVD Segment: Surmodics can drive growth by developing new and innovative products for the in vitro diagnostics market. This includes expanding its portfolio of protein stabilization reagents, substrates, surface coatings, and antigens. Focusing on high-growth areas such as molecular diagnostics and point-of-care testing can further enhance its market position. Timeline: Ongoing, with potential for new product launches in the next 1-2 years.
• Acquisition of Complementary Technologies: Surmodics can pursue strategic acquisitions to acquire complementary technologies and expand its capabilities. This includes acquiring companies with expertise in areas such as biomaterials, drug delivery, and medical device manufacturing. These acquisitions can provide access to new intellectual property, products, and markets, accelerating Surmodics' growth trajectory. The market for medical device acquisitions is active, with numerous opportunities for strategic consolidation. Timeline: Opportunistic, with potential for acquisitions to occur as suitable targets become available.

What Are SRDX's Competitive Advantages?

• Proprietary surface modification technologies create a barrier to entry.
• Strong intellectual property portfolio protects its innovations.
• Established relationships with leading medical device manufacturers provide a competitive advantage.
• Expertise in drug-delivery coatings enhances the value proposition of its products.

What Does SRDX Do?

Founded in 1979 and headquartered in Eden Prairie, Minnesota, Surmodics, Inc. has evolved into a key player in the medical device and in vitro diagnostics industries. The company's initial focus was on developing surface modification technologies to improve the biocompatibility and performance of medical devices. Over the years, Surmodics expanded its expertise to include drug-delivery coating technologies and the design and manufacturing of interventional medical devices, such as balloons and catheters. The company operates through two primary segments: Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment provides surface modification coating technologies that enhance the access, deliverability, and deployment of medical devices. These technologies are crucial for coronary, peripheral, neuro-vascular, and structural heart applications. Surmodics also develops drug-delivery coating technologies for site-specific drug delivery from medical device surfaces, including drug-coated balloons for treating peripheral arterial disease. The IVD segment focuses on designing, developing, and manufacturing component products and technologies for diagnostic immunoassay, molecular testing, and biomedical research. This includes protein stabilization reagents, substrates, surface coatings, and antigens. Surmodics' products are used by medical device manufacturers and diagnostic companies worldwide, contributing to improved patient outcomes and diagnostic accuracy. The company continues to invest in research and development to expand its product offerings and maintain its competitive edge in the healthcare industry.

What Products and Services Does SRDX Offer?

• Develops surface modification technologies for medical devices.
• Provides coating technologies to enhance medical device performance.
• Offers drug-delivery coating technologies for targeted drug delivery.
• Designs and manufactures interventional medical devices, including balloons and catheters.
• Creates component products for diagnostic immunoassays.
• Develops technologies for molecular testing and biomedical research.
• Offers protein stabilization reagents, substrates, surface coatings, and antigens.

How Does SRDX Make Money?

• Generates revenue through the sale of surface modification technologies to medical device manufacturers.
• Earns revenue from the sale of component products for in vitro diagnostics.
• Receives licensing fees for its proprietary technologies.
• Derives revenue from the design, development, and manufacturing of interventional medical devices.

What Industry Does SRDX Operate In?

Surmodics, Inc. operates within the medical device and in vitro diagnostics industries, both experiencing steady growth driven by an aging population, increasing prevalence of chronic diseases, and technological advancements. Surmodics competes with larger medical device manufacturers and specialized coating companies. Its focus on surface modification technologies and drug-delivery coatings positions it as a key enabler for enhancing the performance and functionality of medical devices. The company's success depends on its ability to innovate, secure regulatory approvals, and maintain its competitive edge in a rapidly evolving landscape.

Who Are SRDX's Key Customers?

• Medical device manufacturers seeking to improve device performance and biocompatibility.
• Diagnostic companies requiring components for immunoassay and molecular testing.
• Biomedical research institutions utilizing reagents and coatings for research applications.
• Hospitals and clinics using Surmodics' interventional medical devices for patient treatment.

How Surmodics, Inc. Is Valued

Surmodics, Inc. carries a market capitalization of $615M, placing it in the small-cap category.

Company Profile

Surmodics, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Eden Prairie, US. The company is led by CEO Gary R. Maharaj. SRDX has traded publicly since 1998.

Return on equity for Surmodics, Inc. stands at -9.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -6.2%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.91 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.7%, the inverse of the P/E and a quick read on earnings relative to price.

Surmodics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 7.61 places it in the safe zone, indicating low near-term bankruptcy risk.

Wall Street analysts project Surmodics, Inc. revenue of about $123.0M for fiscal 2026, with EPS near $-0.12.

SRDX Financials

SRDX Latest News

No recent news available for SRDX.

Surmodics, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources